New thrombopoietin receptor agonists for platelet disorders
| Autor: | Paul Batty, C. Bateman, B. Jackson, Roberto Stasi, Yingying Peng, S. Kolade, Caroline Ebdon, S. Homeida |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Blood Platelets
endocrine system Recombinant Fusion Proteins Platelet disorder Eltrombopag Receptors Fc Benzoates chemistry.chemical_compound fluids and secretions Megakaryocyte medicine Animals Humans Pharmacology (medical) Receptor Thrombopoietin Pharmacology Evidence-Based Medicine Romiplostim business.industry Myelodysplastic syndromes Autoantibody food and beverages hemic and immune systems General Medicine medicine.disease Hydrazines Treatment Outcome medicine.anatomical_structure chemistry embryonic structures Immunology Pyrazoles Blood Platelet Disorders business Receptors Thrombopoietin medicine.drug |
| Zdroj: | Drugs of Today. 48:293 |
| ISSN: | 1699-4019 |
| DOI: | 10.1358/dot.2012.48.4.1740505 |
| Popis: | Since thrombopoietin (TPO) was cloned in 1994, TPO receptor (TPO-R) agonists have been developed which have shown significant clinical activity in various conditions characterized by thrombocytopenia. First-generation TPO-R agonists were recombinant forms of human TPO. The clinical development of these molecules was discontinued after one of them, pegylated recombinant human megakaryocyte growth and development factor, was associated with the development of neutralizing autoantibodies cross-reacting with endogenous TPO. Second-generation TPO-R agonists are now available, which present no sequence homology to endogenous TPO. Two of these new agents, romiplostim and eltrombopag, have been granted marketing authorization for use in patients with primary immune thrombocytopenia unresponsive to conventional treatments. Clinical trials with TPO-R agonists are also ongoing in other thrombocytopenias, such as hepatitis C virus-related thrombocytopenia and the myelodysplastic syndromes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|